Work

A phase 1 study of SHR-3821, an ADCC-enhanced CLDN18.2/4-1BB bispecific antibody, in patients with advanced solid tumors.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.4037

Authors: Hongfeng Gou, Li Zheng, Xiuying Xiao, Liwei Wang, Hongli Li, Jieer Ying, Yueyin Pan, Shuqin Ni, Zuoxing Niu, Jun Zhang, Ling Lu, Xiaoyan Lin, Wei He, Wenlong Zhai, Wenhui Yang, Bin Bai, Pingan Yao, Han Cui, Jiankun Hu

Institutions: Sichuan University, West China Hospital of Sichuan University, Shanghai Jiao Tong University, Renji Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Zhejiang Cancer Hospital, Shandong First Medical University, Ruijin Hospital, Union Hospital, First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Shanxi Provincial Cancer Hospital, Jiangsu Hengrui Medicine (China)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162493615

Cites:

Cited by: 1

Related to: